The 2017 JointHealth™ Arthritis Medications Report Card and Medications Guide referred incorrectly to the indications approved for etanercept (Erelzi®)
A biosimilar version of etanercept based upon the reference product etanercept (Enbrel®), etanercept (Erelzi®) was issued a Notice of Compliance by Health Canada on April 5, 2017 for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
We apologize for this oversight. Please kindly make this correction to the printed copy you may have recently received in the mail if you are a print subscriber.
Arthritis Consumer Experts
Arthritis Consumer Experts’ 10th Annual Arthritis Medications Report Card and Medications Guide: The changing landscapes of reimbursement for arthritis medications in Canada
Arthritis Consumer Experts (ACE) has released its 10th Annual JointHealth™ Arthritis Medications Report Card and Medications Guide – the reliable, quick reference tool to help you evaluate where your province ranks in terms of providing reimbursement for medications to treat inflammatory forms of arthritis.
Commenting on the changing landscape for reimbursement of arthritis medications, ACE President, Cheryl Koehn stated: “Any new pharmaceutical policy that promises to deliver significant drug plan savings must do so without compromising patient safety and efficacy. ACE has also consistently advocated that any drug plan cost savings related to changes in policy that affect arthritis medication reimbursement access should be reinvested back to drug formulary budgets to support the listing of new arthritis medicines and other non-medication related initiatives to improve models of arthritis care such as creating rheumatology nursing billing codes.”
The JointHealth™ Arthritis Medications Report Card and Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis, such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis or juvenile idiopathic arthritis.
In this JointHealth™ insight, topics covered include:
- The changing landscapes of reimbursement for arthritis medications in Canada
- The federal health department consultation on medication pricing regulations
- The essential drugs program initiative in British Columbia
- The Children and Youth Pharmacare plan in Ontario
- Medication policies and politics in Canada
About the Report Card